Cohance Lifesciences Limited (NSE:COHANCE)

Cohance Lifesciences Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	11,976	10,514	13,403	13,202	10,097
Other Revenue	-	-	-	-	-0
Revenue	11,976	10,514	13,403	13,202	10,097
Revenue Growth (YoY)	13.91%	-21.56%	1.52%	30.75%	21.10%
Cost of Revenue	3,053	4,503	5,882	5,741	4,372
Gross Profit	8,923	6,010	7,521	7,461	5,725
Selling, General & Admin	2,496	1,403	1,218	1,024	784.18
Research & Development	-	-	-	103.55	110.58
Other Operating Expenses	2,675	516.59	561.82	526.62	415.35
Operating Expenses	5,946	2,465	2,259	2,045	1,626
Operating Income	2,977	3,545	5,262	5,416	4,099
Interest Expense	-123.5	-74.51	-128.11	-62.31	-91.44
Interest & Investment Income	-	20.15	58.32	0.69	2.68
Earnings From Equity Investments	-	-	-	411.12	537.36
Currency Exchange Gain (Loss)	-	81.23	214.38	164.21	95.59
Other Non Operating Income (Expenses)	585.6	65.83	32.9	0.02	0
EBT Excluding Unusual Items	3,439	3,638	5,439	5,930	4,643
Merger & Restructuring Charges	-	-32.24	-	-	-
Gain (Loss) on Sale of Investments	-	449.11	156.87	636.14	33.28
Gain (Loss) on Sale of Assets	-	-0.68	-0.07	106.03	0.34
Other Unusual Items	-	2.73	1.17	3.73	-
Pretax Income	3,439	4,057	5,597	6,676	4,677
Income Tax Expense	791.5	1,054	1,484	2,138	1,053
Earnings From Continuing Operations	2,648	3,003	4,113	4,538	3,623
Minority Interest in Earnings	31	-	-	-	-
Net Income	2,679	3,003	4,113	4,538	3,623
Net Income to Common	2,679	3,003	4,113	4,538	3,623
Net Income Growth	-10.79%	-26.99%	-9.37%	25.24%	14.30%
Shares Outstanding (Basic)	255	255	255	255	255
Shares Outstanding (Diluted)	256	255	255	255	255
Shares Change (YoY)	0.69%	-	-	-	-
EPS (Basic)	10.52	11.80	16.16	17.83	14.23
EPS (Diluted)	10.45	11.80	16.16	17.83	14.23
EPS Growth	-11.41%	-26.99%	-9.37%	25.27%	14.30%
Free Cash Flow	1,325	3,067	1,713	2,548	2,717
Free Cash Flow Per Share	5.17	12.05	6.73	10.01	10.67
Dividend Per Share	-	-	-	2.000	2.000
Dividend Growth	-	-	-	-	60.00%
Gross Margin	74.51%	57.17%	56.11%	56.51%	56.70%
Operating Margin	24.86%	33.72%	39.26%	41.02%	40.59%
Profit Margin	22.37%	28.56%	30.69%	34.37%	35.88%
Free Cash Flow Margin	11.06%	29.17%	12.78%	19.30%	26.91%
EBITDA	3,752	4,063	5,726	5,795	4,407
EBITDA Margin	31.33%	38.65%	42.72%	43.89%	43.65%
D&A For EBITDA	774.9	518.06	464.6	378.64	308.36
EBIT	2,977	3,545	5,262	5,416	4,099
EBIT Margin	24.86%	33.72%	39.26%	41.02%	40.59%
Effective Tax Rate	23.01%	25.98%	26.52%	32.02%	22.52%
Revenue as Reported	12,561	11,133	13,867	14,126	10,240
Advertising Expenses	-	34.78	34.89	18.83	18.37

Source: S&P Global Market Intelligence. Standard template. Financial Sources.